Sahlgrenska Cancer Center, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.
Mol Cell Endocrinol. 2013 Dec 5;381(1-2):241-54. doi: 10.1016/j.mce.2013.08.006. Epub 2013 Aug 19.
Loss of sodium-iodide symporter (NIS) expression in thyroid tumour cells primarily caused by constitutive MAPK pathway activation is often refractory to small molecule MAPK inhibitors. Suggested mechanisms are rebound MAPK signalling and activation of alternative signalling pathways. Here we provide evidence that failure to recover down-regulated NIS by MEK inhibition is not specific to tumour cells. NIS mRNA levels remained repressed in TSH-stimulated primary thyroid cells co-treated with epidermal growth factor (EGF) and pan-MEK inhibitor U0126 in the presence of 5% fetal bovine serum or, independently of serum, in 3D cultured thyroid follicles. This led to inhibited iodide transport and iodination. In contrast, U0126 restituted thyroglobulin synthesis in EGF-treated follicular cells. Serum potentiated TSH-stimulated NIS expression in 2D culture. U0126 blocked down-regulation of NIS only in serum-starved cells with a diminished TSH response. Together, this suggests that morphogenetic signals modify the expression of NIS and recovery response to MEK inhibition.
甲状腺肿瘤细胞中钠碘同向转运体 (NIS) 表达的缺失主要是由于组成性 MAPK 通路的激活,这往往对小分子 MAPK 抑制剂产生抗性。其建议的机制是 MAPK 信号的反弹和替代信号通路的激活。在这里,我们提供的证据表明,MEK 抑制不能恢复下调的 NIS 并不是肿瘤细胞所特有的。在存在 5%胎牛血清的情况下,或独立于血清,在 3D 培养的甲状腺滤泡中,用表皮生长因子 (EGF) 和泛 MEK 抑制剂 U0126 共同处理 TSH 刺激的原代甲状腺细胞时,NIS mRNA 水平仍然受到抑制。这导致碘转运和碘化受到抑制。相比之下,U0126 在 EGF 处理的滤泡细胞中恢复了甲状腺球蛋白的合成。血清增强了 2D 培养中 TSH 刺激的 NIS 表达。U0126 仅在 TSH 反应减弱的血清饥饿细胞中阻断 NIS 的下调。总的来说,这表明形态发生信号改变了 NIS 的表达和对 MEK 抑制的恢复反应。